Literature DB >> 19760063

Overview of TNF superfamily: a chest full of potential therapeutic targets.

Iqbal S Grewal1.   

Abstract

Since the discovery of tumor necrosis factor TNFalpha about 25 years ago, TNF superfamily has grown to a large family of related proteins consisting of over 20 members that signal through over 30 receptors. Members of this superfamily have wide tissue distribution and play important roles ranging from regulation of the normal biological processes such as immune responses, hematopoiesis and morphogenesis to their role in tumorigenesis, transplant rejection, septic shock, viral replication, bone resorption and autoimmunity. Thus, many approaches to harness the potency of TNF superfamily members to treat human diseases have been developed. Indeed, TNF and TNF agonistic molecules have been approved for human use in the United States and other countries. Many other TNF family members show promise for several therapeutic applications, including cancer, infectious disease, transplantation and autoimmunity. This chapter will give overview of TNF superfamily for exploitation for therapeutic use in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760063     DOI: 10.1007/978-0-387-89520-8_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  17 in total

Review 1.  Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors.

Authors:  Devesh Mewar; Anthony G Wilson
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis.

Authors:  Vladimir Vinarsky; Jan Krivanek; Liina Rankel; Zuzana Nahacka; Tomas Barta; Josef Jaros; Ladislav Andera; Ales Hampl
Journal:  Stem Cells Dev       Date:  2013-08-02       Impact factor: 3.272

3.  Lipopolysaccharide and cytokines inhibit rat cardiomyocyte contractility in vitro.

Authors:  Ion A Hobai; Justin C Morse; Deborah A Siwik; Wilson S Colucci
Journal:  J Surg Res       Date:  2014-09-22       Impact factor: 2.192

Review 4.  Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis.

Authors:  Kelby W Wegner; Danish Saleh; Alexei Degterev
Journal:  Trends Pharmacol Sci       Date:  2017-01-23       Impact factor: 14.819

5.  Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling.

Authors:  Cheri Peyton Goodall; Benjamin Schwarz; Ekaterina Selivanovitch; John Avera; Joseph Wang; Heini Miettinen; Trevor Douglas
Journal:  ACS Appl Bio Mater       Date:  2021-11-10

Review 6.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

7.  Ketamine inhibits tumor necrosis factor secretion by RAW264.7 murine macrophages stimulated with antibiotic-exposed strains of community-associated, methicillin-resistant Staphylococcus aureus.

Authors:  Thomas Spentzas; Rebekah K H Shapley; Carlos Acuna Aguirre; Elizabeth Meals; Lauren Lazar; Mark S Rayburn; Brett S Walker; B Keith English
Journal:  BMC Immunol       Date:  2011-01-25       Impact factor: 3.615

Review 8.  Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus.

Authors:  Manfred Relle; Andreas Schwarting
Journal:  Clin Dev Immunol       Date:  2012-06-19

9.  Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.

Authors:  Reem Hamdy A Mohammed; Faisal Farahat; Hanady H Kewan; Mohammed A Bukhari
Journal:  Springerplus       Date:  2015-05-01

10.  Are different stoichiometries feasible for complexes between lymphotoxin-alpha and tumor necrosis factor receptor 1?

Authors:  Nahren Manuel Mascarenhas; Johannes Kästner
Journal:  BMC Struct Biol       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.